Patent intelligence · WO
WO 2025172818
POLYTHÉRAPIE À BASE DE PYRILUTAMIDE
POLYTHÉRAPIE À BASE DE PYRILUTAMIDE
Patent details — WO 2025172818
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Aug 21, 2025
- Expiration
- Aug 16, 2045
- Applicant
- CASSIOPEA S P A [IT]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 506 A I, A61K 31/ 573 A I, A61K 31/ 4174 A I
Quick answer
WO 2025172818 (POLYTHÉRAPIE À BASE DE PYRILUTAMIDE) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Aug 21, 2025. Expires Aug 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CASSIOPEA S P A [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 506 A I, A61K 31/ 573 A I, A61K 31/ 4174 A I, A61K/314174, A61K/31506
More from CASSIOPEA S P A [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026087531
FORMULATIONS DE CLASCOTÉRONE ET LEURS MÉTHODES D'UTILISATION
granted -
WO 2026057588
POLYTHÉRAPIE À BASE DE CLASCOTÉRONE ET DE MINOXIDIL POUR LE TRAITEMENT DE LA PERTE DES CHEVEUX
granted -
WO 2025125508
COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ
granted -
AR 132316
TRATAMIENTO COMBINADO CON CLASCOTERONA Y MINOXIDIL
granted -
WO 2025068281
CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES
granted -
EP 4529925
CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN
granted -
US 2018169113
HIGH CONCENTRATION FORMULATION
granted
Related coverage
Frequently asked questions
What is US patent 2025172818?
WO 2025172818 (POLYTHÉRAPIE À BASE DE PYRILUTAMIDE) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Aug 21, 2025. Expires Aug 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025172818?
CASSIOPEA S P A [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does WO 2025172818 expire?
Our index shows an expiration date of Aug 16, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.